Open Accessclinical and basic science review of Alzheimer's disease
Author(s) -
Ayush Rajendra Ganage,
Ninad Nagrale,
Nandkishor Bankar
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns2.5049
Subject(s) - disease , dementia , neuroimaging , alzheimer's disease , medicine , intervention (counseling) , psychology , psychiatry , pathology
The purpose of this study is to provide a brief overview of Alzheimer's disease and a definition of moderate disability that includes (MCI). This paper focuses on the medical and cardiovascular properties of Alzheimer's disease and Parkinson's. This article also covers the recent advances in the use of biomarkers to diagnose Alzheimer's disease, as well as existing efforts to find new therapies. Alzheimer's disease (AD), the most common form of dementia, affects 50 lakh Indians aged 65 and over, or one in nine. A Clinical and Research Science Review of Alzheimer's Disease. There has been significant progress in identifying pre-dementia stages of Alzheimer's disease, such as MCI, as well as developing diagnosis and therapeutic procedures for treating Alzheimer's disease. Our ability to find a cure for Alzheimer's disease will be determined by our ability to find the right genetic markers for early diagnosis and clinical intervention in patients at risk, as well as a greater understanding of the cellular and molecular processes that go wrong. After the National Institutes of Health (NIA) recognised urgent need to develop clinically useful neuroimaging and other biomarkers for the early detection of Alzheimer's disease, the Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004.